 
      Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
Second quarter net product revenues for ZORYVE® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream 0.3%, and $13.6M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 547% vs. Q2 '23 and 43% vs. Q1 '24 Continued gross-to-net …
 
       
       
       
       
       
       
       
       
       
       
       
       
       
       
  
 
     
     
     
     
     
     
     
     
     
     
     
    